We’re officially one of GenomeWeb’s Best Places to Work 2025!
Read More
Despite unprecedented advances in molecular profiling, precision oncology remains constrained by a fundamental problem: data alone does not translate into decisions. Oncologists are asked to interpret increasingly complex molecular profiles, often without clear guidance when evidence is incomplete, conflicting, or outside textbook pathways.
Genomate Health was founded to address this gap: not by generating more data, but by reasoning over it.
2025 marked a turning point in that mission. Over the course of the year, the company moved decisively from scientific conviction to real-world validation, demonstrating that computational reasoning can support oncology decision-making in clinical practice, meet regulatory expectations, and scale across healthcare systems.
Across science, product, regulation, and commercial execution, we laid the foundations for global impact, while remaining anchored to a single goal: making precision oncology accessible and actionable for every cancer patient.
Most precision oncology tools focus on identifying biomarkers. Genomate takes a fundamentally different approach. Rather than asking whether a single mutation matches a single drug, Genomate applies computational reasoning to evaluate how complex molecular and clinical factors interact, ranking therapies and clinical trials based on their likelihood of benefit for an individual patient.
This approach is designed for the reality of oncology care: heterogeneous tumors, incomplete evidence, and decisions that must be made even when guidelines fall short.
In 2025, this approach was tested rigorously, publicly, and in the real world.
In 2025, Genomate’s computational reasoning approach was validated across both experimental and real-world clinical settings.
A large-scale preclinical study published at AACR 2025 demonstrated the predictive power of Genomate’s drug ranking system in patient-derived xenograft (PDX) models. To the best of our knowledge at the time of publication, this represented the only experimental validation of a computational drug-ranking system at this scale, providing rare, independent evidence that algorithmic reasoning can meaningfully predict treatment response in complex cancers.
This was complemented by real-world clinical validation. Results published in npj Precision Oncology evaluated the performance of Genomate’s universal computational reasoning model in lung cancer, showing its ability to support treatment decision-making beyond single-biomarker logic in real clinical settings.
Together, these studies marked a critical shift: from theoretical promise to demonstrated performance.
Scientific validation in 2025 was matched by early clinical adoption. Over the course of the year, Genomate entered clinical use in the United States, with U.S. oncologists integrating Genomate into real-world decision-making and initial U.S. patients receiving reports powered by computational reasoning.
These early clinical deployments served a dual purpose. They demonstrated the feasibility of using computational reasoning in routine oncology workflows, while generating high-value clinician feedback that directly informed product refinement and go-to-market strategy.
For Genomate Health, this marked an important shift: from developing a scientifically differentiated system to deploying a clinically usable one.
As Genomate moved closer to routine clinical use, regulatory readiness became a central focus. In 2025, Genomate Health achieved three foundational certifications:
These milestones are critical prerequisites for IVDR and FDA pathways, but more importantly, they reflect Genomate Health’s commitment to building clinical-grade software from the ground up.
Moreover, to protect and sustain this innovation, Genomate Health further strengthened its intellectual property portfolio through new trademark registrations across the U.S., EU, and UK, and the receipt of its first EU patent, laying the groundwork for long-term clinical and commercial deployment.
In parallel with clinical and regulatory progress, Genomate Health’s work was examined, debated, and validated across the global oncology community.
Throughout 2025, Genomate Health presented scientific and clinical evidence supporting Genomate® across Europe, the United States, and Asia, engaging researchers, clinicians, patient advocates, and healthcare leaders at some of the most influential oncology, digital health, and cancer informatics forums.
Key engagements included:
Across these engagements, a consistent theme emerged: while molecular data continues to expand, the limiting factor in precision oncology is no longer data generation, but the ability to reason over complexity in a transparent and scalable way.
These global discussions reinforced Genomate Health’s conviction that computational reasoning is not a future concept, but a necessary evolution of precision oncology today.
In 2025, Genomate Health strengthened the foundations for responsibly scaling Genomate® across leadership and culture, research infrastructure, and intellectual property.
A key milestone in this evolution was the appointment of Nabil Hafez as Chief Executive Officer. With deep experience in healthcare commercialization and scaling regulated technologies, Nabil was appointed to lead Genomate Health through its next phase of growth, with a focus on U.S. market expansion, regulatory execution, and commercial readiness.
This leadership transition allowed the company to further align its scientific depth with operational and go-to-market excellence, ensuring that Genomate® can move from early adoption to broader clinical deployment without compromising rigor or quality.
"As Founder, my role was to build a leadership team that brings together deep expertise in science, product development, and commercial execution," said Dr. Petak. "With Nabil's leadership, we are now uniquely positioned to deliver on the first computational solution that can fully implement the promise of precision oncology, while I can focus on advancing the scientific solution behind Genomate and continue my mission to advocate for precision oncology across the globe."
In 2025, the company advanced multiple international research collaborations and grant-supported programs, including participation in Eurostars initiatives, the launch of the BRECISE project, and continued engagement across EU-funded platforms. These efforts support rigorous evidence generation and reinforce Genomate Health’s position at the intersection of science, technology, and real-world clinical impact.
Beyond that, Genomate Health also deepened its role in shaping the broader European digital health ecosystem. Through its Founder and Chief Scientific Officer, Istvan Petak, MD, PhD, the company was invited to the Digital Europe Executive Council of DIGITALEUROPE, contributing a scientific and clinical perspective to pan-European discussions on advanced digital technologies in healthcare.
As Genomate Health scaled its science, product, and operations, it continued to invest deliberately in its people and culture. In 2025, Genomate Health was recognized as one of GenomeWeb’s Best Places to Work, an external acknowledgment of a culture built on scientific rigor, collaboration, and shared purpose. This recognition reflects the company’s belief that building transformative healthcare technology starts with empowered, mission-driven teams held to the highest standards.
That culture is reflected in the leadership and voices shaping the company’s direction. In 2025, Istvan Petak, MD, PhD, Founder and Chief Scientific Officer of Genomate Health, was included in Forbes Hungary’s “AI25 – 25 Hungarians Behind the Artificial Intelligence Revolution”, recognizing his long-standing contributions at the intersection of cancer research, computational science, and healthcare innovation.
By the end of 2025, Genomate Health had crossed a critical threshold. Genomate® had been scientifically validated, deployed in early clinical use, and engaged with regulators as a new category of precision oncology software. The mission has always been clear. In 2025, Genomate Health built the evidence, systems, and momentum required to carry it forward.
As we move into 2026, the focus shifts from proving what is possible to scaling what works: expanding clinical adoption, advancing regulatory pathways, and continuing to build evidence that supports equitable access to precision oncology.
.avif)
.png)